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doi:10.1016/j.ejvs.2011.02.029Abstract Objective: Lymphoedema is a common complication after cancer treatment. We
have reported that low-energy extracorporeal shock wave (SW) therapy up-regulates vascular
endothelial growth factor (VEGF) in ischaemic myocardium. As VEGF plays an important role in
lymphangiogenesis, we investigated whether our low-energy SW therapy enhances lymphan-
giogenesis in rats.
Methods: We created a tail model of lymphoedema in rats. The tail was treated with or
without low-energy SW therapy (0.25 mJ mm2, 500 impulses) four times (days 3, 5, 7, and
9). The tail volume and the fluorescence intensity of indocyanine green (ICG) were measured.
The expression of VEGF-C and basic fibroblast growth factor (bFGF) were evaluated by RT-PCR,
and the lymphatic vessel density was assessed histochemically.
Results: The tail volume increased significantly in the control group and was significantly
improved in the SW group. The lymphatic system function (evaluated with fluorescence inten-
sity of ICG), the lymphatic vessel density, and the expression of VEGF-C and bFGF were all
enhanced by the SW therapy (all P < 0.05).
Conclusions: The low-energy SW therapy induces therapeutic lymphangiogenesis by up-regu-
lating VEGF-C and bFGF, and improves lymphoedema in a rat-tail model, suggesting that
low-energy SW therapy could be a non-invasive and effective strategy for lymphoedema in hu-
mans.
ª 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.2 717 7214; fax: þ81 22 717 7217.
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Extracorporeal Shock Wave Therapy for Lymphoedema 255Lymphoedemaoccurs as a result of an imbalance between the
demand for lymphatic flow and the capacity of the lymphatic
circulation.1 It is characterised by the regional accumulation
of excess amounts of interstitial protein-rich fluid. Lymphoe-
dema is a slowly progressive, usually painless swelling of the
extremities. Primary lymphoedema is caused by develop-
mental abnormalities of the lymphatic vessels. Secondary
lymphoedema is the result of acquired obstruction of the
lymphatic vessels and lymph nodes. Secondary lymphoedema
is a major complication after surgery or radiation treatment
for cancer, and the number of patients affected is
increasing.2,3 The standard treatments for lymphoedema are
compression andmanual drainage, whichmerelymitigate the
symptoms. Therefore, new and effective therapies remain to
be developed. Reconstructing the lymphatic circulation
system is one promising strategy for lymphoedema.
We have previously demonstrated that low-energy
extracorporeal shock wave (SW) therapy effectively induces
therapeutic angiogenesis and improves myocardial
ischaemia in pigs andhumansaswell as hindlimb ischaemia in
rabbits, through up-regulation of vascular endothelial
growth factor (VEGF).4e8 VEGF-C plays an important and
essential role in lymphangiogenesis.9,10 Basic fibroblast
growth factor (bFGF) can also induce lymphangio-
genesis,11,12 and its effect ismediated viaVEGF-C and -D.13 In
the present study, we examined whether low-energy SW
therapy improves lymphoedema in a rat model of tail lym-
phoedema and if so, whether VEGF and bFGF are involved.
Materials and Methods
Animals
Male Sprague-Dawley rats (CLEA Japan, Tokyo, Japan)
weighing 200e250 g were used (nZ 90). The animals were
cared for in accordance with the principles and guidelines of
the Japanese Ministry of the Environment. The protocols of
the present study were approved by the ethics committee on
animal experiments of Tohoku University (no. 22-303).
Secondary lymphoedema model in the rat
On day 1, we performed surgery to cause secondary lym-
phoedema in rat tails. The rat-tail model of secondary
lymphoedema has been described previously.14,15 Anaes-
thesia was induced with diethyl ether and maintained with
the intra-peritoneal injection of pentobarbital (30 mg kg1)
during surgery. Two parallel circumferential incisions were
made 5 mm apart through the dermis, close to the tail base.
The skin band and subcutaneous tissues, including
lymphatic vessels, were removed completely. Lymphatic
vessels were identified with the subcutaneous injection of
0.5% Evans blue dye. The major underlying blood vessels
and tendon were preserved to prevent the distal tail from
becoming necrotic. Both skin edges were cauterised with
a radio knife for haemostasis and to delay wound closure.
Postoperatively, the animals were randomly divided into
the control and the SW groups. First, we treated 30 rats to
measure tail volume; 15 for the control group and the
remaining 15 for the SW group. On day 25, all animals were
euthanised. Among them, 12 (six from each group) wereused for RT-PCR analysis and another 12 for histochemical
analysis; the remaining six were used for blood test.
Second, we treated 48 rats (24 in each group) and
euthanised 24 rats (12 from each group) on day 7 and 15,
respectively. Among them, 12 (six from each group) were
used for RT-PCR analysis and another 12 for histochemical
analysis. Third, we treated additional 12 (six from each
group) to evaluate lymphatic system function using indoc-
yanine green (ICG) and an infrared camera. Thus, we used
a total of 90 rats in this study.
Extracorporeal SW therapy
One SW treatment consisted of 0.25 mJ mm2 (total energy
flux density), 500 impulses, using a SW generator (DUOLITH
SD1; Storz Medical, Switzerland) based on our previous
studies, in which maximal up-regulation of VEGF expression
was achieved at w0.1 mJ mm2 (positive energy flux
density).4e8 According to the manufacturer, 0.1 mJ mm2
(positive energy flux density) is equivalent to 0.25 mJ mm2
(total energy flux density). Animals in the SW group received
low-energy SW therapy to the surgical site four times (post-
operative days 3, 5, 7 and 9), whereas those in the control
group received the same procedures but without the SW
treatment.
Tail volume measurement
Tail volume was measured using water displacement volu-
metry every 3 days (n Z 15 per group).16
Evaluation of lymphatic system function
Lymphatic system functionwas evaluated by the ICGmethod
(nZ 6 per group). Briefly, we injected 0.1 mg of ICG (Daiichi
Sankyo, Japan) subcutaneously in theend of the tail on day 1.
As the injected ICG was absorbed in the lymphatic ducts and
transported from the tail to the body, the fluorescence
intensity gradually decreased. We evaluated the drainage
function of lymphatic fluid by measuring the average fluo-
rescence intensity with an infrared camera (PDE System
C9830; Hamamatsu Photonics, Japan) at the distal area of
the surgical site every 2 days. The camera was fixed at 20 cm
from the tail, and the measured area was 4.4  20 mm.
RT-PCR analysis
All tissues except bone were harvested from the surgical site
on days 7, 15 or 25 (n Z 6 per group). The samples were
homogenised and used for total RNA extraction with a TRIzol
PlusRNApurificationkit (LifeTechnologies Japan, Japan).RNA
concentrations were determined using GeneQuant Pro (Bio-
chrome, UK). Reverse transcriptase M-MLV (2640A, Takara
Bio, Japan), three gene-specific primer pairs (SigmaeAldrich
Japan), and a LightCycler 2.0 (Roche Diagnostics, Tokyo,
Japan) were used for PCR. The primers were as follows
(50 / 30): for VEGF-C (286-bp fragment), GCCAATCACACT
TCCTGCCG (sense) and CTGGCAGGTGTCTTCATCCAAC (anti-
sense); for bFGF (225-bp fragment), CCAGTTGGTATGT
GGCACTG (sense) and CAGGGAAGGGTTTGACAAGA (anti-
sense); and for b-actin (612-bp fragment), ATATCGCTGC
256 F. Serizawa et al.GCTCGTC (sense) and TTTCCCTCTCAGCTGTGGT (anti-sense).
ThePCRconditions forVEGF-Cwere40cycles of1minat 94 C,
90 s at 55 C, and 90 s at 72 C. The PCR conditions for bFGF
were 40 cycles of 30 s at 94 C, 60 s at 56 C, and 105 s at 72 C.
The expression levels of the two genes were compared
between the SWandcontrol groups.Values are reportedas the
quotientsof thecopynumberof thegeneof interest relative to
that of b-actin, as a housekeeping gene (VEGF-C/b-actin or
bFGF/b-actin). The PCR reaction mixtures (20 ml) were sepa-
rated electrophoretically in 2% agarose gels containing
ethidium bromide, observed, and photographed under ultra-
violet light.
Histochemical examination
The surgical site was excised, including 1 cm on each side on
days 7, 15 or 25 (nZ 6 per group). The samples were fixed
with formalin, embedded in paraffin, and divided into two
parts for staining: one with haematoxylin and eosin (HE) and
the other with D2-40 (code: 413451, mouse monoclonal;
Nichirei, Japan), an antibody against a lymphatic-specific
marker.17 We measured the thickness of the dermis and
subcutaneous tissue just distal to the surgical site in the HE-
stained samples (original magnification,200), and used the
D2-40-stained samples to assess lymphatic vessel density
(originalmagnification,400). The number of D2-40-positive
vessels was counted in randomly selectedmicroscopic fields,
and the results areexpressedas thenumber ofD2-40-positive
vessels/field. The observer counting the lymphatic vessels
was blinded to treatment allocation of the rats. All histo-
chemical examinations were performed with a BX51
microscope (Olympus, Japan).
Statistical analyses
Statistical analyses were performed with the unpaired
t-test using StatMate 4. The results are expressed as
means  standard deviations (SDs). Differences were
considered statistically significant at P < 0.05.Figure 1 Representative photographs of rat tails. On postoperati
control group whereas the edema in the SW group was modest.Results
Tail volume
Until day 4, the tail volume increased similarly in both groups.
After day 4, the tail volume further increased in the control
group, whereas it decreased in the SW group (Figs. 1 and 2). A
significant difference in the tail volume was observed
between the two groups fromdays 7e19 (day 10: 7.0 0.8 vs.
8.4 0.4ml; day 19: 7.0 0.6 vs. 8.2 0.2ml, bothP< 0.05).
Lymphatic system function
The average fluorescence intensity value was significantly
lower in the SW group than in the control group (P < 0.05) on
days 7, 13, 23, and 25 (Fig. 3). These data indicate that the
drainage of lymphatic fluid was enhanced by the SW therapy.
RT-PCR analysis
VEGF-C expression was significantly up-regulated in the SW
group compared with the control group on days 7 and 15
(day 7: 1.52  0.47 vs. 0.83  0.14; day 15: 1.03  0.02 vs.
0.54  0.01, both P < 0.05), as was bFGF expression (day 7:
0.41  0.21 vs. 0.15  0.03; day 15: 1.01  0.27 vs.
0.59  0.05, both P < 0.05) (Fig. 4).
Histochemical examination
In the HE-stained histological specimens, the dermis and
subcutaneous tissue of the control group were significantly
swollen, as comparedwith the SWgroup, ondays 7 and15 (day
7: 408 74 vs. 555 45mm;day 15: 371 67 vs. 536 60mm,
both P < 0.05) (Fig. 5). Upon immunostaining with D2-40,
a specific marker of lymphatic vessels, newly formed
lymphatic vessels were readily visualised in the subcutaneous
tissue in the SW group. On days 15 and 25, the number of
lymphatic vesselswas significantly higher in the SWgroup thanve day 7, severe oedema and skin redness were observed in the
Figure 2 Time course of tail volume. The SW therapy sup-
pressed lymphedema. Up to day 4, lymphedema developed to
a similar extent in both groups. On day 7, the tail volume had
further increased in the controls, whereas it had started to
decrease in the SWgroup. The difference in tail volume between
the two groups was statistically significant from days 7e19.
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day 25: 4.8 0.7 vs. 3.2 0.8 per field, both P< 0.05) (Fig. 6).
Biochemical analysis
No significant differences were observed between two
groups (total protein: 5.8  0.12 vs. 5.8  0.16; albumin
2.4  0.04 vs. 2.3  0.08). All results were shown in Table 1.
Discussion
The novel finding of the present studywas that low-energy SW
therapy induced effective therapeutic lymphangiogenesis in
a rat model of secondary lymphoedema, and which was
accompanied by the up-regulation of VEGF-C and bFGF.Figure 3 Representative images of fluorescence intensity measu
the SW group, the average fluorescence intensity was lower than iBeneficial effects of SW therapy on lymphoedema
In the present study, the increased tail volume decreased
significantly in the SW group with a significant increase in
the number of D2-40-positive vessels at the site of surgery
as compared with the control group. These results indicate
that low-energy SW therapy enhanced lymphangiogenesis,
thus reducing the lymphoedema. We also examined the
removal rate of injected ICG from the distal part of the
surgical site by measuring its fluorescence intensity with an
infrared camera. Until day 5, the fluorescence intensity
decreased similarly in both groups. The fluorescence
intensity was significantly lower in the SW group than in the
control group during the experimental period following SW
therapy. These results indicate that low-energy SW therapy
enhanced the drainage of lymphatic fluid. The fluorescence
intensity in the control group also decreased between days
3 and 5 without any treatment, even though most of the
superficial lymphatic system was removed by the surgery.
Thus, it is possible that some ICG drained through the deep
lymphatic vessels or diffused through deep tissues.Mechanisms for the beneficial effects of SW therapy
on lymphoedema
VEGF-C and bFGF are important factors for lymphangio-
genesis.9e12,18 VEGF-C gene transfer reduces lymphoedema in
several animal models.9,10,16 In the present study, the
expression of VEGF-C and bFGF was enhanced significantly at
the surgical site, where low-energy SW therapy was applied,
suggesting that VEGF-C and bFGF were up-regulated by the
low-energy SW therapy with a resultant therapeutic lym-
phangiogenesis. Recently, Kubo et al. also reported that low-
energy SW therapy induced lymphangiogenesis and amelio-
rated secondary lymphoedema in rabbit-ear model.19 Theyrement (right) and the average fluorescence intensity (left). In
n the controls. The red arrows indicate the SW therapy.
Figure 4 Expression of VEGF-C and bFGF in a surgical site specimen. In the SW group, the expression of VEGF-C and bFGF was
significantly enhanced on days 7 and 15, as compared with the control group.
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expression of VEGF-C and VEGFR3, and lymphatic duct count.
In both their and our studies, SW therapy reduced the
increased skin thickness, up-regulated theexpressionofVEGF-
C, and increased the lymphatic duct count. These results
suggest that the SWtherapyenhances up-regulationofVEGF-C
leading to lymphangiogenesis. It is possible that the mechan-
ical stress causedbythe low-energySW, suchas cavitation (the
formation of vapour bubbles in a flowing liquid) and shear
stress,20,21 induced VEGF-C and bFGF up-regulation. Further
investigation is needed to clarify the detailed mechanisms of
the beneficial effects of low-energy SW therapy.
Animal models of secondary lymphoedema
Several animal models of secondary lymphoedema have
been reported, including rabbit-ear- and rat- or mouse-tail
models.14e16,19,22,23 In the present study, we used the rat-
tail model because it allows precise measurements of the
compartment volume. Pathologically, secondary lymphoe-
dema results from a decreased transport capacity of the
lymphatic system due to acquired lymphatic vessel orFigure 5 Time course of subcutaneous tissue thickness. The
SW therapy reduced the lymphedema compared with the
control group.lymph node obstruction. The result of this condition is the
stagnation of lymphatic fluid in the affected compartment,
which is directly reflected in the compartment volume.
Therefore, tail volume measurement would be superior to
assessing skin thickness in evaluating the severity of lym-
phoedema. In fact, a heterogeneous distribution of lym-
phoedema in the same compartment is often observed in
humans.24
Limitations
Several limitations of the present study should be
mentioned. First, lymphoedema in the present rat-tail
model might be different from that in humans. Rats have
a powerful healing ability, and lymphoedema in the rat tail
heals almost completely even with no treatment. By
contrast, secondary lymphoedema in humans is always
slowly progressive and does not recover naturally. No
exact animal model of chronic secondary lymphoedema in
humans is available. Nevertheless, the results of this study
suggest that low-energy SW therapy may be effective, at
least, in the acute phase of secondary lymphoedema in
humans. Second, the optimal therapeutic condition is not
clear. Low-energy SW therapy has been used to treat
a variety of diseases, such as ischaemic heart disease,
hindlimb ischaemia, and orthopaedic disorders; however,
the doses and number of applications vary among studies
(0.037e0.62 mJ mm2, 100e12 000 impulses).4e8,19,25e29
Regarding the SW level, we have previously demon-
strated that VEGF expression peaks at w0.1 mJ mm2
(positive energy flux density),4,6 and according to the
manufacturer, 0.1 mJ mm2 (positive energy flux density)
is equivalent to 0.25 mJ mm2 (total energy flux density).
Thus, in the present study, we employed 0.25 mJ mm2.
Regarding the number of SW impulses, the most effective
number of impulses is unknown for lymphoedema.
However, in the clinical trial of the SW therapy for severe
angina pectoris, satisfactory outcome was achieved with
4000e8000 impulses.5,8 As the human heart (200e300 g) is
about 15 times as heavy as the rat tail (15e20 g), we
Figure 6 Time course of lymphatic vessel density. The number of D2-40-positive vessels (red arrow) per field was increased
significantly in the SW group as compared with the control group on days 15 and 25. Bar, 50 mm.
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lymphangiogenesis. Regarding the number of treatment
series, when we started the present study, we were not
sure how many series of SW therapy were most effective.
However, on day 7 (after two series of SW therapy), the tail
volume began to decrease and the difference between the
SW and the control groups became significant. On day 10
(after four series of SW therapy), significant difference
became more clear. Thus, we considered that four series
of SW therapy are sufficient for the present study. Further
studies are required to find the optimal condition for each
disease. Third, the number of rats used in this study might
have been small for a well-grounded conclusion. Fourth,
we must consider the anti-inflammatory effects of low-
energy SW therapy. Because low-energy SW therapy
suppresses inflammation,30 it is possible that low-energy
SW therapy could reduce lymphoedema through an anti-
inflammatory effect as well.Clinical implications
Althoughpatientswith lymphoedema suffer fromphysical and
psychological impairments,31,32 the available treatment
options are limited. Traditional compression treatments withTable 1 No significant differences were observed
between two groups.
Control (n Z 3) SW group
(n Z 3)
Total protein (g/dl) 5.8  0.12 5.8  0.16
Albumin (g/dl) 2.4  0.04 2.3  0.08
AST (I.U/I) 82  10.6 84  9.2
ALT (I.U/I) 31  3.1 28  3.3
HGB (g/dI) 15.4  0.66 15.8  0.71
Ht (%) 44.2  1.00 44.4  1.06a bandage or manual lymph drainage are not curative. Lym-
phatico-venous anastomosis is effective for lymphoe-
dema,33,34 but is invasive and requires a surgeon skilled in
microsurgery. Thus, it is desirable to develop a safe, non-
invasive treatment for lymphoedema. In this study, we
demonstrated that low-energy SW therapy ameliorated lym-
phoedema by enhancing lymphangiogenesis in rats. Further-
more, no side effects were observed. Because of no need for
anaesthesia or invasive procedures, low-energy SW therapy
might be suitable even for patientswith severe lymphoedema
that required repeated therapy. However, we need further
consideration before clinical use because the rat-tail model is
not exactly fit for the lymphoedema in humans.Conclusions
We demonstrated that low-energy SW therapy enhanced
lymphangiogenesis and improved secondary lymphoedema
in rats, suggesting that the low-energy SW therapy may
have a potential to be a safe and non-invasive strategy for
treating lymphoedema in humans.Acknowledgements
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